Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2002

View Archived Issues

High-titered canarypox vaccine in combination with gp120 proved safe and immunogenic

Synthetic tumstatin-derived peptide exerts promising antiangiogenic and antitumor activity

Water-soluble, orally bioavailable prodrug of Ro-31-7453 designed at Roche

JS-K, an arylated diazeniumdiolate, undergoes evaluation at the NCI

Promising in vitro anti-HBV activity described for MCC-478 this week at JSGE meeting

Edaravone has no effect on cerebral blood flow after acute stroke

Potential of MS-818 in stroke suggested by preclinical experiments

KB-R7785 ameliorates cardiac hypertrophy induced by GPCR agonists

Better cardioprotection of allografts reported for a combination of diazoxide and TY-12533

FR-190997, a highly potent, nonpeptide bradykinin receptor agonist with vasorelaxant activity

Ghrelin induces GH release and enhances cardiac performance in healthy humans

Joint French and Japanese R&D program discovers GSK-3beta inhibitors

Integrin inhibitors and their potential uses patented by Ajinomoto

Boehringer Ingelheim claims new tyrosine kinase-inhibitory 4-aminoquinazolines

Carboxamides synthesized at Ono show selectivity as EP3 and/or EP4 receptor antagonists

New PDE5 inhibitors in the Merck pipeline

Preparation and use of PTP1B inhibitors described by Abbott

Hokuriku Seiyaku investigates new treatments for cytokine-mediated disorders

Xalatan approved in E.U. as first-line therapy for lowering IOP in glaucoma patients

Genentech licenses Xenova's OX40/OX40 ligand technology

Phase I/IIa trial initiated for TLK-199 in myelodysplastic syndrome

Lynx and Wilex collaborate to identify genes regulated by WX-G250

Regulatory approval sought in Japan for Visudyne in AMD

Customized vaccine tested in NHL patients at University of Maryland

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...